Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: A pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs

Clinical Neuropharmacology

Volumn 26, Issue 3, 2003, Pages 142-145

  Gony, Mireille ^a   Lapeyre Mestre, Maryse ^a   Montastruc, Jean Louis ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Antidepressants; Extrapyramidal symptoms; Parkinson's disease; Serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; BROMOCRIPTINE; CITALOPRAM; DIAZEPAM; ENALAPRIL; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; LITHIUM; LORMETAZEPAM; MOLSIDOMINE; PAROXETINE; RILMENIDINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; THYROXINE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG MONITORING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIDEPRESSIVE AGENTS; BASAL GANGLIA DISEASES; DEPRESSIVE DISORDER; HUMANS; PARKINSON DISEASE; RISK FACTORS;

EID: 0038390077     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200305000-00007     Document Type: Article

References (25)

1. Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997;49:1168-70.
2. Zesiewicz TA, Gold M, Chari G, et al. Current issues in depression in Parkinson's disease. Am J Geriatr Psychiatry 1999;7:110-8.
3. Dooneef G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-7.
4. Allain H, Schuck S, Mauduit N. Depression in Parkinson's disease. BMJ 2000;320:1287-8.
5. Caley CF. Extrapyramidal reactions and the selective serotoninreuptake inhibitors. Ann Pharmacother 1997;31:1481-9.
6. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitorinduced movement disorders. Ann Pharmacother 1998;32:692-8.
7. Extrapyramidal effects of SSRI antidepressants. Prescrive Int 2001;10:118-9.
8. Moore N, Noblet C, Kreft-Jais C, et al. The French Pharmacovigilance Database system. Thérapie 1995;50:557-62.
9. Report of CIOMS working groups III and IV: guidelines for preparing cote-clinical safety information on drugs. Geneva: CIOMS, 1999.
10. Begaud B, Evreux JC, Jouglard J. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Thérapie 1985;40:111-8.
11. Montastruc JL, Fabre N, Blin O, et al. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Mov Disord 1995;10:355-7.
12. Ceravolo R, Nuti A, Piccini A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-8.
13. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15:986-9.
14. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-7.
15. Strom BL. When should one perform pharmacoepidemiology studies? In: Strom, BL, ed. Pharmacoepidemiology. 3rd ed. New York: Wiley, 2000:63-72.
16. Montastruc JL, Lapeyre-Mestre M, Bagheri H, et al. Intérêt de la pharmacoépidémiologie pour le praticien. Rev Prat (Paris) 2002;52:701-3.
17. Van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of antidepressant drugs in Parkinson's disease: association with the disease and its course. Int J Geriatr Psychopharmacol 2000;3:148-52.
18. Van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002;54:168-70.
19. Schilleoort I, Van Puijenbroek EP, De Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002;17:75-9.
20. Cuadrado JI, De Pedro-Cuesta J, Abraira V, et al. Epidemiological assessment of levodopa use in Spain, 1990-1995. Persistent, low consumption in the south. Pharmacoepidemiol Drug Saf 1999;8:433-45.
21. Van de Vijver DAMC, Roos RAC, Jansen PAF, et al. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiol Drug Saf 2001;10:549-54.
22. Van de Vijver DAMC, Stricker BHCH, Breteler MMB, et al. Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharmacy World Sci 2001;23:148-52.
23. Sa DS, Kapur S, Lang AL. Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. Clin Neuropharmacol 2001;24:242-4.
24. Bareille MP, Montastruc JL, Lapeyre-Mestre M. Liver damage and non steroidal antiinflammatory drugs: a case/non-case study in the French Pharmacovigilance Database. Therapy 2001;56:51-5.
25. Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reaction to selegiline: a review of the French Pharmacovigilance Database. Clin Neuropharmacol 2000;23:271-5.